Spectrum of Central Anticholinergic Adverse Effects Associated with Oxybutynin: Comparison of Pediatric and Adult Cases

• Published in: The Journal of pediatrics Vol. 155; no. 3; pp. 432 - 434
• Main Authors: Gish, Paula, RPh, Mosholder, Andrew D., MD, MPH, Truffa, Melissa, RPh, Johann-Liang, Rosemary, MD
• Format: Journal Article
• Language: English
• Published: Maryland Heights, MO Mosby, Inc 01.09.2009; Elsevier
• Subjects: Adolescent; Adult; Adverse Drug Reaction Reporting Systems - statistics & numerical data; Age Factors; Biological and medical sciences; Central Nervous System - drug effects; Child; Child, Preschool; Databases as Topic; General aspects; Humans; Infant; Mandelic Acids - administration & dosage; Mandelic Acids - adverse effects; Medical sciences; Middle Aged; Muscarinic Antagonists - administration & dosage; Muscarinic Antagonists - adverse effects; Nervous System Diseases - chemically induced; Nocturnal Enuresis - drug therapy; Pediatrics; Young Adult; CNS; FDA; Food and Drug Administration; Central nervous system; Human; Pediatrics; Toxicity; Spectrum; Cholinergic receptor; Anticholinergic agent; Association; Antispasmodic agent; Antimuscarinic agent; Secondary effect; Adult; Muscarinic receptor; Oxybutynin; Antagonist; Anticholinesterase agent; Child; Comparative study
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/j.jpeds.2009.01.074

We reviewed Food and Drug Administration postmarketing reports of central nervous system (CNS) anticholinergic effects in association with oxybutynin. Taking domestic usage by age group into account, there is a disproportionately higher number of CNS adverse event cases reported in pediatric patients as compared with adult patients. CNS stimulation was prominent in the pediatric cases.